Newron Pharmaceuticals has reported favourable results from a Phase IIa clinical trial of its evenamide (NW-3509)for treatment of patients with schizophrenia.

Evenamide is a new chemical entity designed to target and block voltage-gated sodium channels, as well as normalise glutamate release caused by abnormal sodium channel activity.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The results from the trial indicated that evenamide as an add-on therapy has met the study objectives of tolerability, safety and preliminary efficacy.

The four-week, double-blind, placebo-controlled, randomised, multi-national Phase IIa trial evaluated the objectives in 89 subjects with a DSM-5 diagnosis of schizophrenia.

"Results indicated that evenamide might provide significant evidence of efficacy as an add-on to the most commonly prescribed atypical antipsychotics in patients with chronic schizophrenia."

Newron chief medical officer Ravi Anand said: "The results of this first study in patients with schizophrenia confirm preclinical data, which indicated that evenamide might provide significant evidence of efficacy as an add-on to the most commonly prescribed atypical antipsychotics in patients with chronic schizophrenia, without effect on any of the over 130 neurotransmitters, enzymes, or transporters targeted by most antipsychotics."

See Also:

Conducted at two US and three Indian sites, the trial involved patients with a mean duration of illness of around 18 years and an average of three hospitalisations.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The results showed that patients demonstrated improvement on the symptoms of schizophrenia measured by the positive and negative syndrome scale (PANSS).

Evenamide was also found to have potential benefits in preclinical models with psychiatric diseases, psychosis such as amphetamine-induced hyperactivity, sensorimotor gating and information processing deficits, as well as mania, depression, aggression and compulsive behaviour.